GSEP
MREO

Golden State Equity Partners’s Mereo BioPharma MREO Stock Holding History

Golden State Equity Partners’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,900
Closed -$41K – 514
2025
Q3 		$41K Hold
19,900
– – 0.01% 447
2025
Q2 		$53.9K Hold
19,900
– – 0.01% 432
2025
Q1 		$44.8K Sell
19,900
-2,700
-12% -$7.64K 0.01% 429
2024
Q4 		$79.1K Buy
22,600
+16,100
+248% +$63.3K 0.02% 429
2024
Q3 		$26.7K Sell
6,500
-18,300
-74% -$75.7K 0.01% 476
2024
Q2 		$89.3K Buy
+24,800
New +$80.3K 0.02% 397
2023
Q4 		$46.9K Buy
20,300
+5,900
+41% +$11.3K 0.01% 357
2023
Q3 		$18.6K Hold
14,400
– – 0.01% 335
2023
Q2 		$19K Hold
14,400
– – 0.01% 369
2023
Q1 		$10.2K Buy
+14,400
New +$13K 0.01% 214
2022
Q1 		$23K Hold
20,300
– – 0.01% 192
2021
Q4 		$32K Buy
+20,300
New +$40.6K 0.02% 173

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Golden State Equity Partners's MREO Position: Q4 2025 in Review

Golden State Equity Partners sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 19,900 shares — an estimated $41K sold.

Golden State Equity Partners first reported a position in MREO in Q4 2021 and held it in 12 quarters. The position peaked at $89.3K in Q2 2024. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • Golden State Equity Partners reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
  • Golden State Equity Partners sold 19,900 Mereo BioPharma shares in Q4 2025, an estimated $41K.
  • Golden State Equity Partners first reported a position in Mereo BioPharma in Q4 2021 and held it in 12 quarters.
  • Golden State Equity Partners's Mereo BioPharma position peaked at $89.3K in Q2 2024.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Golden State Equity Partners's 13F filing for Q4 2025, filed 29 Jan 2026.